Tempus AI, Inc. (TEM)
Nasdaq · Chicago, Illinois, USA · Founded 2015 · CEO Eric Lefkofsky
Valuation summary
Fair value is not meaningful for this company — the model produces a negative equity value. Rated Sell.
| Fair value per share | N/M |
| Current share price | $59.61 |
| Upside / downside | -103.7% |
| Bear case | N/M |
| Bull case | $4.44 |
| Discount rate (WACC) | 11.9% |
| Terminal growth | 3.20% |
| Market capitalisation | $11B |
| EV / Sales | 7.7x |
About Tempus AI, Inc.
Founded in 2015 by Eric Lefkofsky, the co-founder of Groupon, after his wife was treated for cancer. He is chief executive. Tempus sequences the DNA of patients' tumours to help doctors choose treatments, and has assembled one of the largest libraries of clinical and genetic data, which it licenses to drug companies for research. It listed in 2024 and bought the hereditary-testing company Ambry Genetics in 2025.
Investment case
- Each test adds to a data library that becomes more valuable as it grows.
- Most large drug makers already buy its data.
- Testing volumes are rising quickly and losses are narrowing.
Key risks
- Not yet consistently profitable.
- Reimbursement for genetic tests is uncertain.
- Competes with Guardant, Natera, Foundation Medicine and Caris.
Revenue by segment
| Genomic testing | 75% |
| Data and services | 25% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $2.1B | $-0.1B |
| Year 2 | $2.7B | $-0.1B |
| Year 3 | $3.3B | $-0.0B |
| Year 4 | $3.8B | $0.0B |
| Year 5 | $4.2B | $0.1B |
What the street says
Marketed as an AI company in healthcare; sceptics see a testing lab on a technology valuation.
Comparable companies: NTRA · ALNY · HIMS · HUM · CAH · CNC · DXCM · MDLN
Open the interactive model, price chart and sensitivity grid →